The Committee for Medicinal Products for Human Use (CHMP) is the committee that is responsible for preparing the Agency's opinions on all questions concerning human medicines.
European Medicines Agency, Amsterdam, the Netherlands
Startdatum:
11 November 2024
Enddatum:
14 November 2024
EventHumanMedicines
Online
European Medicines Agency, Amsterdam, the Netherlands
Startdatum:
8 November 2024, 10:00 (CET)
Enddatum:
8 November 2024, 11:00 (CET)
EventHumanRegulatory and procedural guidance
European Medicines Agency, Amsterdam, the Netherlands
Startdatum:
7 November 2024
Enddatum:
7 November 2024
EventHumanAdvanced therapies
Online
Startdatum:
6 November 2024, 10:00 (CET)
Enddatum:
6 November 2024, 13:30 (CET)
EventHumanMedicine shortages
European Medicines Agency, Amsterdam, the Netherlands
Startdatum:
6 November 2024
Enddatum:
8 November 2024
EventHumanAdvanced therapiesInnovation
This is a questions and answers (Q&A) session on the Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API).
Online
European Medicines Agency, Amsterdam, the Netherlands
Startdatum:
5 November 2024, 10:00 (CET)
Enddatum:
5 November 2024, 10:30 (CET)
EventHumanData on medicines
Online
European Medicines Agency, Amsterdam, the Netherlands
Live broadcast
Startdatum:
5 November 2024, 09:00 (CET)
Enddatum:
5 November 2024, 17:40 (CET)
EventCorporate
European Medicines Agency, Amsterdam, the Netherlands
Startdatum:
5 November 2024
Enddatum:
7 November 2024
EventHumanRare diseases
European Medicines Agency, Amsterdam, the Netherlands
Startdatum:
5 November 2024
Enddatum:
7 November 2024
EventVeterinaryMedicines
EudraVigilance is the EU's system for managing and analysing information on adverse reactions to medicines which have been authorised or are being studied in clinical trials in the European Economic Area (EEA) and supports the reporting and analysis of suspected adverse reactions originating from clinical trials and the post-authorisation phase of...
Online
Startdatum:
4 November 2024
Enddatum:
8 November 2024
EventHumanClinical trials